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Abstract Glioblastoma is dependent on a speciﬁc signal-
ing pathway to maintain its tumor phenotype. The receptor
tyrosine kinase (RTK) family mediates the multiple onco-
genic growth factor receptor signaling and contributes to the
pathogenesis of glioblastoma. Recently, many studies have
shown that the expression of stem cell marker in glioblas-
toma tissue has prognostic signiﬁcance, which indicates that
thequantiﬁcationofstemcellmarkersandRTKgenesyields
biological information about glioblastoma. In this study, we
quantiﬁed RNA expression levels of stem cell markers
[CD133, Nestin, BMI-1, maternal embryonic leucine zipper
kinase (MELK), and Notch1–4] as well as RTKs (EGFR,
ErbB4,VEGFR1-3,FGFR1,-2,PDGFRA,andPDGFRB)in
42 clinical samples of glioblastoma by the real-time
RT-PCR method. We demonstrated that the expression of
MELK is exclusively upregulated in glioblastoma tissue.
Notch receptor expression is moderately upregulated and is
correlated with that of VEGFR2, VEGFR3, and PDGFRb.
Unsupervised clustering identiﬁed one unique sample group
that showed high expression of most of the genes analyzed.
Our results suggest that quantiﬁcation of these stem cell
markers and RTK genes can stratify patients based on the
expression proﬁle, which might provide insight into the
glioma biology in each cluster.
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Introduction
Glioblastoma is the most common malignant primary brain
tumor in adults. Despite surgery, radiation, and chemo-
therapy, the median survival after diagnosis is approxi-
mately 12 months. As shown by the Cancer Genome Atlas
pilot project, receptor tyrosine kinase (RTK) signaling
pathways such as epidermal growth factor receptor (EGFR)
and platelet-derived growth factor receptor (PDGFR) are
frequently altered and activated in glioblastomas [1]. Drugs
targeting these oncogenic signaling pathways have shown
clinical activity in patients with glioblastomas, and targeted
therapy represents a promising new paradigm for the
treatment of glioblastomas [2, 3]. Thus, it is of particular
importance to evaluate the activation of each RTK pathway
in glioblastomas for the development of effective molec-
ular targeted therapy.
It has been recently reported that the expression of some
stem cell markers in glioblastoma has prognostic signiﬁ-
cance [4–9]. Although Nestin and CD133, which are the
most accredited, are useful stem cell markers, they are
known to be expressed also in non-stem cell populations
and play an important role in gliomagenesis. Notch,
maternal embryonic leucine zipper kinase (MELK), and
BMI-1 (a polycomb gene) are other signaling molecules
implicated in the stem cell signaling pathway [10–12].
However, the expression proﬁles and functional roles of
these molecules in glioblastoma tissue have not been sys-
tematically investigated. We hypothesized that exploring
the stem cell signaling pathway in conjunction with the
RTK pathway in glioblastoma tissues would yield prog-
nostic information for patients in the clinic. Furthermore, it
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well as the RTK pathway could be molecular targets for a
new treatment strategy.
Recent advancements in microarray technology have
enabled us to investigate genome-wide molecular proﬁling
and identify a new molecular target. This high-throughput
technology, however, is expensive, and it cannot always be
integratedintotheclinicalsetting,wheremethodologythatis
easier to use and more cost effective is preferred. Real-time
reverse transcription-polymerase chain reaction (RT-PCR)
technology is easily integratedin the clinic. In this study, we
quantiﬁedtheexpressionofstemcellmarkergenesandRTK
genes in glioma tissue using a real-time RT-PCR method,
performedunsupervisedhierarchalclustering,andevaluated
the statistical correlation of these expression data.
Materials and methods
Tumor specimens
We collected 42 case samples of glioblastoma from the
Kyushu University Brain Tumor Bank; these samples were
obtained from patients during surgery under the approval
of the ethics committee of our university. For all tumors,
a histological diagnosis of glioblastoma was determined
based on World Health Organization criteria by board-
certiﬁed neuropathologists. All 42 cases were primary
glioblastomas; secondary glioblastomas and recurrent cases
were excluded from this study. Normal brain reference
RNA (NBRR) was purchased from Ambion and used as an
internal control.
Target genes and primer design
Concerning stem cell marker genes, we evaluated the
expression of CD133 and Nestin, which are currently the
most accredited markers forthe identiﬁcation of neural stem
cells. In addition, MELK and BMI-1 were included in this
study because these genes contribute to stem cell mainte-
nance. Notch receptors (Notch1–4) were also included in
this study because the Notch signaling pathway is impli-
cated in the maintenance of neural progenitors and in the
generation of glia during development of the brain and is
altered in gliomas [13, 14]. Of all the RTK genes, we
selected nine genes that have been shown to be involved in
tumor growth and proliferation in glioblastomas: EGFR,
ErbB4, VEGFR1, VEGFR2, VEGFR3, FGFR1, EGFR2,
PDGFRA, and PDGFRB. In total, 17 genes were included
in this study. Ampliﬁcation primer pairs were designed for
nonredundant regions on the NCBI Reference Sequence
(RefSeq) using Primer 3 software. The target genes and
corresponding RefSeq are listed in Table 1.
RNA extraction, reverse transcription, and real-time
reverse transcription-polymerase chain reaction
Total RNA was extracted from the frozen samples using a
commercial mirVana miRNA isolation kit (Ambion, Aus-
tin, TX, USA). Reverse transcriptions were performed by
random hexamers using a High Capacity cDNA Reverse
Transcription kit (Applied Biosystems, Carlsbad, CA,
USA). Reverse-transcribed products were ampliﬁed by the
SYBR method using the ABI PRISM 7500 Fast Real-time
PCR System (Applied Biosystems). Brieﬂy, 2 ll cDNA
product was used as a template in a 20-ll PCR reaction
containing 10 ll Power SYBR Green Master Mix (Applied
Biosystems), 200 mM each primer, 1 ll dimethylsulfoxide
(DMSO), and 6.2 ll distilled water. Hypoxanthine phos-
phoribosyltransferase 1 (HPRT1) was used as a reference
gene. Ampliﬁcation protocols were as follows: 95C for
10 min, 40 cycles of 95C/15 s, and 40 cycles of 60C/60 s
with melting curve analysis. Threshold cycle number (CT)
was automatically determined by ABI 7500 Fast System
SDS software. All reactions were performed in duplicate.
Data analysis of quantitative RT-PCR and statistical
analysis
The average CT value of duplicate runs was determined for
each gene, and DCT was calculated by subtracting the CT
value of the HPRT1 reference gene from that of each gene.
The relative expression of each gene was quantiﬁed by the
DDCT method. In this method, DDCT was calculated by
Table 1 List of genes analyzed in this study
Gene Chromosome map Reference sequence
(Ref Seq)
EGFR 7p12 NM_005228
ERBB4 2q33 NM_001042599
PDGFRA 4q12 NM_006206
PDGFRB 5q31 NM_002609
FGFR1 8p12 NM_015850
FGFR2 10q26 NM_000141
VEGFR1 13q12 NM_002019
VEGFR2 4q11 NM_002253
VEGFR3 5q35 NM_002020.4
Notch1 9q34 NM_017617
Notch2 1p12 NM_024408
Notch3 19p13 NM_000435
Notch4 6p21 NM_004557
Nestin 1q23 NM_006617.1
MELK 9p13 NM_014791
BMI-1 10p13 NM_005180
CD133 4p15 NM_006017
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gene, and the relative quantity (RQ) was calculated. To
auto-scale the data for clustering, the RQ of each gene was
divided by the mean RQ value of all samples, and the data
were presented as log10 of this value. Hierarchical clus-
tering using Ward’s linkage analysis and Spearman’s rank
test was performed by JMP 8 statistical software (SAS
Institute, Cary, NC, USA).
Results
Quantiﬁcation of stem cell markers and RTK genes
Ampliﬁed products were successfully obtained for all
genes. The CT value of NBRR was less than 35 in all genes
except MELK, for which the CT value was 38.4, indicating
that MELK expression is very low or absent in healthy
brain tissue. The RQ value was box-plotted as log-trans-
formed numbers (Fig. 1). For each gene, outlying cases in
the upper and lower 10% of expression were not plotted in
this ﬁgure. In glioblastoma tissues, EGFR, PDGFRA,
Nestin, MELK, and CD133 are strongly expressed com-
pared to normal brain tissue. Notably, MELK expression is
exclusively upregulated in glioblastoma tissue without
quantiﬁable expression in normal brain tissue. The
expression of VEGFR2, VEGFR3, FGFR1, PDGFRB, and
Notch1–3 are slightly higher than that in normal brain
tissue. Notably, the stem cell marker BMI-1 showed
decreased expression in glioblastoma tissues. In total, the
median RQ value of ErbB4, VEGFR1, FGFR2, and BMI-1
was less than 1, which showed that the expression level of
each of these genes is less than or equal to that in normal
brain tissue.
Hierarchical clustering categorized glioma tissues
into three clusters
To compare the expression proﬁles of the different samples
and detect groups of samples with similar expression pro-
ﬁles, we performed hierarchical clustering of the expres-
sion data of the 13 genes (excluding ErbB4, VEGFR1,
FGFR2, and BMI-1) with higher expression compared with
normal brain tissue. The dendrogram of this clustering
demonstrated that all 42 glioma tissues could be catego-
rized into three clusters (Fig. 2). Although we could not
conclude the expression proﬁle of samples within cluster 1,
cluster 2 showed a high level of expression of almost all
genes including stem cell markers and RTKs, and cluster 3
showed a low level of expression of all genes.
Spearman’s rank test of genes with strong correlation
of expression
To evaluate the correlation of the expression patterns
among these 13 genes, we performed pairwise Spearman’s
correlation tests. Strong correlation was detected among
Notch1–4, PDGFRB, VEGFR2, and VEGFR3 (Table 2.
There were no signiﬁcant correlations among stem cell
markers.
Fig. 1 The relative quantity
value (RQ) normalized by
normal brain reference RNA is
shown as a log-transformed
number for 17 genes. The
bottom and top of the box
indicate lower and upper
quartiles, respectively. The
band at the middle of the box
indicates the median value of all
samples. Upper and lower bars
indicate the upper 90th
percentile and lower 10th
percentile, respectively. For
each gene, outliers of this range
were not plotted in this ﬁgure
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Our results demonstrated that the expression of MELK, an
atypical member of the snﬂ/AMPK family of serine-thre-
onine kinases, which are key regulators of the proliferation
and maintenance of glioma stem cells, is exclusively
upregulated in glioblastoma tissues in contrast to Nestin,
CD133, and Notch, expression of which is also detected in
normal brain tissue. The RQ of MELK expression is the
same or higher than that of EGFR, which has been known
to be overexpressed in glioblastoma tissue. It has been also
reported that MELK expression is positively increased
according to tumor grade [15]. Our results therefore imply
that the MELK signaling pathway can be a therapeutic
target for glioblastomas.
The relative quantiﬁcation of RTK genes in this study is
consistent with previous studies [16–19]. EGFR is the
most highly expressed gene, followed by PDGFRA. The
expression of PDGFRB is lower than that of PDGFRA, and
VEGFR2 and -3 are more highly expressed than VEGFR1.
Regarding other stem cell markers, Nestin and CD133 [20],
the two most accredited stem cell markers, are expressed in
the same range, although their expression is not tumor
speciﬁc, which suggests that the biological signiﬁcance of
the expression of these markers should be thoroughly
investigated. The Notch pathway is a conserved ligand–
receptor signaling mechanism that modulates cell fate and
differentiation and plays an important role in the mainte-
nance of stem cell self-renewal. In mammals, there are four
Notch receptors (Notch1–4) and ﬁve ligands (Jagged1, -2;
Delta-like1, -3, -4) [14]. Although the key components of
this Notch signaling are reported to be aberrantly activated
in gliomas and are considered to be implicated in
gliomagenesis, the quantiﬁcation of these four Notch
receptors in gliomas has been inadequately investigated
[21]. Our results demonstrated that Notch1 and Notch2 are
upregulated by 5- to 20 fold compared with normal tissue,
whereas the expression of Notch3 and Notch4 is threefold
higher on average, which might suggest that Notch1 and
Notch2 signaling are more important than that of Notch3
and Notch4. Conversely, the results of BMI-1 expression in
our study showed a discrepancy with previous studies.
Although it has been reported that BMI-1 inhibits activa-
tion of the tumor suppressor pathway and its expression is
highly upregulated in glioblastomas [22], our results
revealed that BMI-1 expression is not upregulated com-
pared with normal tissue. Further study is needed to
address this discrepancy.
Our clustering data demonstrated that 42 glioma tis-
sues could be classiﬁed into three groups based on the
Fig. 2 Hierarchical clustering analysis demonstrated that all the
samples could be classiﬁed into three clusters based on the analysis of
13 genes. In cluster 2, samples show high expression of most of the
genes. By contrast, expression of all the genes is low in cluster 3
Table 2 List of gene combinations with strong correlation of gene
expression
Genes Correlation
coefﬁcient
Notch4 versus VEGFR3 0.92
Notch4 versus VEGFR2 0.88
VEGFR3 versus VEGFR2 0.88
Notch3 versus PDGFRB 0.84
Notch2 versus Notch1 0.79
Notch3 versus Notch2 0.79
Notch3 versus VEGFR3 0.78
Notch3 versus Notch4 0.78
Notch3 versus VEGFR2 0.74
Notch1 versus VEGFR3 0.73
PDGFRB versus VEGFR2 0.73
Notch2 versus PDGFRB 0.72
PDGFRB versus VEGFR3 0.72
Correlation coefﬁcient was obtained by Spearman’s rank test. All
these correlation coefﬁcients were statistically signiﬁcant
(P\0.0001)
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123expression of 13 stem cell markers and RTK genes. The
demonstrative feature of this clustering is that gliomas in
cluster 2 show relatively high expression of all genes,
whereas the expression of all genes is relatively low in
cluster 3. Further studies are needed to evaluate whether
this subclassiﬁcation can be applied to larger sample sets
and whether this clustering has prognostic signiﬁcance,
because we have not included prognostic information in
this study. Furthermore, because a recent study has repor-
ted a glioblastoma molecular stratiﬁcation deﬁned as pro-
neural, neural, classical, and mesenchymal based on
genomic alteration [23–25], we need to evaluate how each
unique cluster falls into these categories.
The clustering data also give us a general description of
how the selected genes co-varied with respect to their
expression level, and some of the correlation is conﬁrmed
by statistical analysis. Pairwise Spearman’s correlation
analysis on all genes revealed high correlation coefﬁcients
in some pairs (see Table 2). Notably, genes listed in
Table 2 are all implicated in the angiogenesis of normal
and tumor tissue. We did not see strong statistical corre-
lations among stem cell markers MELK, Nestin, CD133,
and Notch receptors. In addition, there is a possibility that
gene pairs with moderate correlation may have been mis-
sed with these criteria, because we have only listed the
gene pairs for which the correlation coefﬁcient is more than
0.7. In fact, the correlation coefﬁcient of EGFR and Nestin,
and of PDGFRA and CD133, both of which are in the same
gene tree in the dendrogram, was 0.68 (P\0.0001) and
0.55 (P = 0.0002), respectively.
In summary, we demonstrated that the expression of
MELK is exclusively upregulated in glioblastoma tissue.
Although Notch receptor expression is moderately upreg-
ulated in glioblastoma tissue, its expression showed a
strong correlation with angiogenesis-related genes VEG-
FR2, VEGFR3, and PDGFRB. We need to address the
biological and prognostic features of glioblastomas
grouped within cluster 2 because this group showed the
unique ﬁndings that all the genes are highly expressed.
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